Chairman Roskam, Ranking Member Levin, and distinguished Members of the Committee:

Thank you for giving ASIPP this opportunity to provide our views on reforming approaches to curb drug overdose deaths and improve care of chronic pain with nonopioid treatments.

I am Dr. Ramsin Benyamin and I am the Medical Director of Millennium Pain Center, a practice with other physicians in Bloomington, IL. I am also Clinical Assistant Professor of Surgery, College of Medicine, at University of Illinois, Urbana-Champaign, IL, and Adjunct Research Professor, Department of Psychology, at Illinois Wesleyan University, Bloomington, IL. I have participated in multiple clinical trials and published over 150 peer-reviewed articles. I also have clinics in Peoria, Decatur, Pekin, Champaign, Libertyville, and Chicago, IL. I have been in the practice of interventional pain management for over 20 years. In the past, I have served as President of the American Society of Interventional Pain Physicians (ASIPP) and I am currently on the Board of Directors of that society. I am the President of the Illinois Society of Interventional Pain Physicians.

The American Society of Interventional Pain Physicians is a not-for-profit professional organization founded in 1998 now comprising of over 4,500 interventional pain physicians and other practitioners who are dedicated to ensuring safe, appropriate and equal access to essential pain management services for patients across the country suffering with chronic and acute pain. There are approximately 8,500 appropriately trained and qualified physicians practicing interventional pain management in the United States. ASIPP is comprised of 50 affiliated state societies, and the Puerto Rico Society of Interventional Pain Physicians. As an organization, ASIPP began issuing warnings and offering preventive measures in early 2000 with its proposal of a national program --- the National All Schedules Prescription Electronic Reporting Act (NASPER), which eventually was signed into law as a state-run prescription drug monitoring program in 2005. As you know, I am happy to state that all 50 states now have PDMPs. In fact,
mandatory provider review of prescription drug monitoring programs and pain clinic laws have shown to reduce the amounts of opioids prescribed by 8% and prescription opioid overdose death rates by 12%. In addition, it has also been shown that relatively large reductions in heroin overdose death rates after implementation of mandatory prescription drug monitoring programs and pain clinic laws as of 2015.\textsuperscript{1} ASIPP also offers extensive educational efforts for pain physicians including a variety of review courses and competency examinations.

Interventional pain management is defined as the discipline of medicine devoted to the diagnosis and treatment of pain related disorders principally with the application of interventional techniques in managing sub acute, chronic, persistent, and intractable pain, independently or in conjunction with other modalities of treatment.\textsuperscript{2}

Interventional pain management techniques are minimally invasive procedures including, percutaneous precision needle placement, with placement of drugs in targeted areas or ablation of targeted nerves; and some surgical techniques such as laser or endoscopic discectomy, intrathecal infusion pumps and spinal cord stimulators, for the diagnosis and management of chronic, persistent or intractable pain.\textsuperscript{3}

Unfortunately, opioid deaths continue to increase at a dramatic pace despite reductions in opioid prescriptions since 2010.\textsuperscript{4} No doubt opioid prescriptions are still explosive with the amount of opioids prescribed in the United States continuing to be 3 times higher than in 1999, the year ASIPP developed our idea of the National All Schedules Prescription Electronic Reporting Act (NASPER). Yet, in 2017, the national opioid epidemic continues to show escalation. Drug overdoses accounted for 64,000 deaths in 2016, with over 42,000 of opioid deaths, a 20% increase from 2015 from over 52,000. Increases are greatest for overdoses related to the category including illicitly manufactured fentanyl, which more than doubled, accounting for more than 20,000 overdose deaths in 2016 versus less than 10,000 deaths in 2015. This difference is enough to

\textsuperscript{1} Dowell D, Zhang K, Noonan RK, Hockenberry JM. Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. \textit{Health Aff (Millwood)} 2016; 35:1876-1883.
\textsuperscript{2} The National Uniform Claims Committee. Specialty Designation for Interventional Pain Management- 09. \url{www.cms.hhs.gov/transmittals/Downloads/r1779b3.pdf}
account for nearly all increases in drug overdose deaths from 2015 to 2016.\textsuperscript{5,6} Consequently, while fentanyl contributed to 20,000 deaths, heroin contributed to 15,000 deaths, whereas prescription drugs contributed to less than 15,000 deaths (Figs. 1-3).\textsuperscript{4,7} Deaths due to heroin were up nearly 20% and deaths from other opioids such as hydrocodone and oxycodone were up 14%. Deaths due to methadone declined; however, they still constitute an extremely high percentage with over 3,000 deaths, which is only 1% of prescriptions. As we all realize, things might very well be worse than what is shown in the data. The present problem of overdose deaths is mainly due to illicit fentanyl and heroin use with contributions from prescription opioids. As you may know, Fentanyl is approximately 50 times as potent as heroin. This provides strong economic incentives for drug dealers to mix fentanyl with heroin and other drugs because smaller volumes can provide equally powerful effects at lower costs and easier transport.\textsuperscript{5} Ironically, the majority of people who use heroin are not seeking fentanyl and essentially try to avoid it.\textsuperscript{8} However, technology has improved so much that it is difficult to identify fentanyl, particularly in white powder form, and heroin is typically sold more in states, east of Mississippi river.\textsuperscript{9}

\textsuperscript{7} Ingraham C. CDC releases grim new opioid overdose figures: ‘We’re talking about more than an exponential increase.’ \textit{The Washington Post}, December 21, 2017. \url{https://www.washingtonpost.com/news/wonk/wp/2017/12/21/cdc-releases-grim-new-opioid-overdose-figures-were-talking-about-more-than-an-exponential-increase/?utm_term=.f3f893febb8b}.
Fig. 1. Annual opioid prescribing rates, by number of days’ supply, average daily morphine milligram equivalent (MME) per prescription, and average number of days’ supply per prescription — United States, 2006–2015.


4
**Fig. 2. Opioid deaths surge in 2016. Number of opioid overdose deaths by category, 1999 to 2016.**

Fig. 3. Opioid deaths surge in 2016. Number of opioid overdose deaths by category, 1999 to 2016.

Source: Ingraham C. CDC releases grim new opioid overdose figures: ‘We’re talking about more than an exponential increase.’ The Washington Post, December 21, 2017.

In addition, recent data shows that the number of people presenting for opioid treatment with heroin abuse has increased from 8.7% in 2005 to 33.3% in 2015. There also has been an increase in self-reported fentanyl use among the population entering drug treatment from 9% in 2013 to 15% in 2016, referred to as “unknown fentanyl” products. Consequently, the number of prescription opioid admissions is declining and illicit fentanyl and heroin admissions are increasing.

Thus far, the effectiveness of numerous interventions to curb opioid epidemic has been limited, including prescription drug monitoring programs, pain clinic laws, treatment of opioid use disorder, guidelines, and numerous other policies.

As a result of this disturbing trend, we, at ASIPP are suggesting more effective legislative efforts to curb opioid abuse and reduce opioid deaths, while maintaining appropriate access, and the promotion of nonopioid modalities including interventional techniques. Consequently, we, at ASIPP propose a 3-tier approach to achieve these goals.

Tier 1 includes the following:

1. An aggressive public education campaign with explicit teaching on the dangers of the use of illicit drugs, specifically heroin and fentanyl.
2. A public education campaign relating to the adverse consequences of opioid abuse in general with emphasis on the adverse consequences in combination with benzodiazepines.
   - A recent survey published in the *New England Journal of Medicine* shows that the public blame the opioid crisis on physicians, pharmacists, and pharmaceutical companies without putting much responsibility on patients. Forty-six percent of the public puts the blame on doctors who inappropriately prescribe medication (33%) and 13% put the blame on pharmaceutical companies that sell prescription medication but only 28% blame people who sell prescription pain killers illegally and 10% put the blame on people who take prescription pain killers.\(^\text{13}\)
   - In addition, the public believes that public education and awareness programs are effective in a large proportion of patients.
3. Mandatory physician education for all prescribers of any amount of opioids or benzodiazepines with a mandated requirement of 4 hours of continuing education per year.


4. Mandatory patient education associated with the first prescription of any amount of opioid.

Tier 2 includes the following:

5. Easier access to, and low or no copayments for, nonopioid techniques including physical therapy and interventional techniques which could potentially reduce the medication use and improve patient’s functions and outcomes.\(^\text{12}\)

- Ironically, as reimbursement of interventional techniques has decreased with decreasing utilization since 2010, opioid deaths have been escalating.\(^\text{14}\)

- Evidence shows a direct relationship between the decline in utilization of interventional techniques and increase in the number of opioid deaths since 2010 (Figs. 4 and 5).

---


---

**Fig 4.** Comparative analysis of epidural and adhesiolysis procedures, facet joint interventions and sacroiliac joint blocks, disc procedures and other types of nerve blocks, and all interventional techniques.
6. Expand low-threshold access to buprenorphine for opioid use disorder.\textsuperscript{5,15,16}

It has been shown that a substantial proportion of patients who would benefit from buprenorphine treatment will receive this only if it becomes more attractive and more accessible than either prescription or illicit opioids.\textsuperscript{15}

- Opioid overdose deaths have been shown to decrease 79\% over a period of 6 years after widespread prescribing of buprenorphine in France.\textsuperscript{16} This will also lead to availability of buprenorphine and its products for chronic pain management.

\textsuperscript{15} Kolodny A. Ten steps the federal government should take now to reverse the opioid addiction epidemic. \textit{JAMA} 2017; 318:1537-1538.

7. Establishment of enhanced prescription drug monitoring program (PDMP) with National All Schedules Prescription Electronic Reporting Act (NASPER) program, with each state with a mandated capacity to be able to interact with at least all bordering states.

8. Mandated review of PDMP data by all providers, prior to all prescriptions.

Tier 3 includes the following:

9. Buprenorphine must be available for chronic pain management in addition to medication-assisted treatment, with a change of controlled substance scheduling to a Schedule II drug.

10. Remove methadone from formulary, which is responsible for over 3,000 deaths per year with only 1% of total prescriptions.

Finally, it is essential to develop treatment paradigms for patients with true somatic causes of pain. Nonopioid techniques have been recommended by IOM and attorney generals of many states. Yet, these have not been adequately considered. In fact, reductions and cuts continue to make difficulties to being able to utilize physical therapy, interventional techniques, and ironically even nonopioid medical therapy options.17,18

Thank you again for providing our organization with the opportunity to testify before Congress and provide our views.

It has been an honor to be here with you today. If you have any questions, I will be happy to answer.

---
